AstraZeneca
rare disease and total revenue in driven by continued neurology growth rare disease key dynamics franchise sustainable durable growth driven by demand growth in neurology indications continued conversion to partly offset by growth in emerging markets beyond complement market expansion and increased demand and driven by continued global demand | AstraZeneca
Company
Deck Type
Sector
Industry
Deck date
November 2024
Slide
22 of 38
Similar slides by AstraZeneca
See diffirences between slides (animation)
Results
February 2024
rare disease and total revenue in driven by neurology and patient demand rare disease key dynamics and sustained leadership with durable and growth | AstraZeneca
Related slides by other companies
Deliveroo
Results
January 2023
group continued per order growth driven by in and consumer fee inflation a | Deliveroo
Oatly
Results
February 2025
we have continued to drive broad based growth | Oatly
IBEX
Investor Presentation
November 2023
highly diversified industry verticals | IBEX
Coursera
Investor Presentation
April 2023
degrees return to growth driven by increased student enrollments and scaling of new program launches me | Coursera
Other recent decks by AstraZeneca
See all presentations (31 decks)
Results
February 2025
Results
November 2024
Investor Event
September 2024
Results
February 2024
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io